NCT07620691 N95 Masks for Lung Health While Golfing During Wildfire Season
| NCT ID | NCT07620691 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Saskatchewan |
| Condition | Bronchial Asthma |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-05-26 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-05-26 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Lung health is negatively affected during wildfire season by increased smoke pollution. Wearing N95 masks protects lung health in the short-term. The purpose of our study is to assess whether wearing of N95 facemasks on days with moderate to high air pollution in people who go outside to golf on a regular basis (two or more times per week) for two months during the wildfire season projects lung health.
Eligibility Criteria
Inclusion Criteria: * Golf on a regular basis (two or more times per week) Exclusion Criteria: * Smoker
Contact & Investigator
Philip Chilibeck, PhD
PRINCIPAL INVESTIGATOR
University of Saskatchewan
Frequently Asked Questions
Who can join the NCT07620691 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Bronchial Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07620691 currently recruiting?
Yes, NCT07620691 is actively recruiting participants. Contact the research team at phil.chilibeck@usask.ca for enrollment information.
Where is the NCT07620691 trial being conducted?
This trial is being conducted at Saskatoon, Canada.
Who is sponsoring the NCT07620691 clinical trial?
NCT07620691 is sponsored by University of Saskatchewan. The principal investigator is Philip Chilibeck, PhD at University of Saskatchewan. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.